Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about AZNCF
Recent news which mentions AZNCF
< Previous
1
2
3
4
5
6
7
Next >
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
January 25, 2022
Tickers
AZN
AZNCF
VALN
Tags
News
COVID/19 Vaccine
Biotech
From
Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
January 24, 2022
Tickers
AZN
AZNCF
BNTX
JNJ
Tags
BNTX
Health Care
JNJ
From
Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
January 24, 2022
Tickers
AZN
AZNCF
IONS
Tags
Health Care
Briefs
AZN
From
Benzinga
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
January 21, 2022
Tickers
AZN
AZNCF
BNTX
MRNA
Tags
COVID/19 Vaccine
News
Biotech
From
Benzinga
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
January 19, 2022
Tickers
AZN
AZNCF
Tags
Benzinga
Briefs
AZN
From
Benzinga
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
January 13, 2022
Tickers
AZN
AZNCF
Tags
Government
Contracts
Health Care
From
Benzinga
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use
January 13, 2022
Tickers
AZN
AZNCF
Tags
Briefs
AZN
Health Care
From
Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
January 13, 2022
Tickers
ADGI
AZN
AZNCF
GSK
Tags
Movers
COVID/19 Coronavirus
AZNCF
From
Benzinga
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins
January 13, 2022
Tickers
AZN
AZNCF
Tags
Health Care
AZNCF
Market News
From
Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
January 03, 2022
Tickers
AZN
AZNCF
OVID
Tags
OVID
AZNCF
Market News
From
Benzinga
Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron
December 23, 2021
Tickers
AZN
AZNCF
BNTX
PFE
Tags
Briefs
AZN
BNTX
From
Benzinga
AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma
December 20, 2021
Tickers
AMGN
AZN
AZNCF
Tags
AMGN
Market News
AZNCF
From
Benzinga
Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
December 17, 2021
Tickers
AZN
AZNCF
BNTX
JNJ
Tags
AZN
Briefs
BNTX
From
Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
Tickers
AZN
AZNCF
REGN
Tags
COVID/19 Coronavirus
Market News
AZNCF
From
Benzinga
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
December 15, 2021
Tickers
AZN
AZNCF
BNTX
GSK
Tags
COVID/19 Coronavirus
AZNCF
Market News
From
Benzinga
Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy
December 14, 2021
Tickers
AZN
AZNCF
Tags
COVID/19 Coronavirus
AZNCF
Market News
From
Benzinga
AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK
December 10, 2021
Tickers
AZN
AZNCF
Tags
Health Care
Market News
AZNCF
From
Benzinga
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
December 09, 2021
Tickers
AZN
AZNCF
IPHA
Tags
Movers
Penny Stocks
AZNCF
From
Benzinga
AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised
December 09, 2021
Tickers
AZN
AZNCF
Tags
AZN
Briefs
Health Care
From
Benzinga
Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response
December 07, 2021
Tickers
AZN
AZNCF
BNTX
MRNA
Tags
AZN
Briefs
Health Care
From
Benzinga
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
December 07, 2021
Tickers
AZN
AZNCF
IONS
Tags
Market News
AZNCF
IONS
From
Benzinga
Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population
December 03, 2021
Tickers
AZN
AZNCF
BNTX
PFE
Tags
VALN
AZN
Briefs
From
Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
December 03, 2021
Tickers
AZN
AZNCF
BIOVF
Tags
News
Biotech
General
From
Benzinga
Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots
December 02, 2021
Tickers
AZN
AZNCF
Tags
General
News
COVID/19 Vaccine
From
Benzinga
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
November 30, 2021
Tickers
AZN
AZNCF
MRK
Tags
Market News
AZNCF
Benzinga
From
Benzinga
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
November 12, 2021
Tickers
AZN
AZNCF
MRNA
PFE
Tags
COVID/19 Vaccine
News
Biotech
From
Benzinga
AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report
November 10, 2021
Tickers
AZN
AZNCF
Tags
COVID/19 Coronavirus
AZNCF
Market News
From
Benzinga
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
November 01, 2021
Tickers
AZN
AZNCF
INO
Tags
AZNCF
Market News
Benzinga
From
Benzinga
AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M
November 01, 2021
Tickers
AZN
AZNCF
Tags
Health Care
Market News
AZNCF
From
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
October 26, 2021
Tickers
AZN
AZNCF
Tags
AZN
Briefs
Health Care
From
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.